# How to Measure Unbound Drug Target in a Sample

> This patent describes a laboratory method for accurately measuring the amount of a specific target molecule (antigen) that is not yet bound by a complex drug (multispecific antibody) in a sample, which is important for drug development.

- **Patent:** US 20210055304
- **Original title:** Method for the detection of a binding partner of a multispecific binder
- **Owner:** Hoffmann La Roche
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, diagnostics

## What it does

This method helps scientists determine the amount of 'free antigen' in a sample that also contains a 'multispecific antibody' drug. First, the sample is mixed with a 'second antigen' that specifically attaches to a different part of the multispecific antibody, forming a 'second antigen-multispecific antibody complex' (Claim 11). This complex is then removed from the sample (Claim 11), leaving behind a 'multispecific antibody-depleted sample'. Finally, the amount of the original free antigen in this depleted sample is measured (Claim 14). For example, if a drug binds to both a cancer cell marker and a blood protein, this method allows researchers to precisely measure how much of the cancer cell marker is still available, not yet bound by the drug.

## What it does NOT cover

- Does not cover methods for detecting free antigen of a monospecific antibody (an antibody that only binds to one type of target).
- Does not cover methods that measure the total amount of antigen, only the *free* or unbound antigen.
- Does not cover methods that do not involve removing the multispecific antibody from the sample before measuring the free antigen.
- Does not cover methods where the multispecific antibody is depleted using an anti-idiotypic antibody instead of a 'second antigen'.
- Does not cover methods where the second antigen binds to the *same* binding specificity as the first antigen.

## The clever bit

The clever part is specifically removing the multispecific antibody from the sample *before* measuring the free antigen. This is done by using a 'second antigen' that binds to a *different* part of the drug, ensuring that only the truly unbound target molecule is measured, preventing the drug from interfering with the measurement.

## Real-world examples

1. Development of bispecific antibodies for cancer immunotherapy
2. Measuring drug-target engagement for multispecific antibodies in clinical trials
3. Pharmacokinetic studies for complex biologic drugs
4. Research into autoimmune disease treatments using multispecific antibodies

## Why it matters

Accurately measuring free antigen is critical in the development and testing of new antibody drugs. It helps researchers understand how much of a drug is actually available to bind to its intended target in the body, which directly impacts drug dosing, effectiveness, and safety. This method provides a way to get a clearer picture of drug-target engagement without interference from the drug itself.

## Frequently asked questions

### What does How to Measure Unbound Drug Target in a Sample cover?

This patent describes a laboratory method for accurately measuring the amount of a specific target molecule (antigen) that is not yet bound by a complex drug (multispecific antibody) in a sample, which is important for drug development.

### Who owns patent US 20210055304?

This patent is owned by Hoffmann La Roche.

### When does this patent expire?

This patent is expected to expire on July 31, 2040, when the invention enters the public domain.

### What problem does this patent solve?

Accurately measuring free antigen is critical in the development and testing of new antibody drugs. It helps researchers understand how much of a drug is actually available to bind to its intended target in the body, which directly impacts drug dosing, effectiveness, and safety. This method provides a way to get a clearer picture of drug-target engagement without interference from the drug itself.

### What does this patent NOT cover?

Does not cover methods for detecting free antigen of a monospecific antibody (an antibody that only binds to one type of target).

**Full plain-English explainer:** https://patentbrief.org/patent/us/20210055304/method-for-the-detection-of-a-binding-partner-of-a-multispecific-binder

**Original patent:** https://patents.google.com/patent/US20210055304

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._